Masimo (MASI) Stock Price, News & Analysis

Company Overview

Masimo Corporation is a global medical technology company specializing in innovative noninvasive monitoring solutions. Headquartered in Irvine, California, Masimo develops and manufactures advanced patient monitoring systems that measure oxygen saturation, pulse rate, and other vital signs using proprietary signal processing technologies. Its flagship product, Masimo SET® (Signal Extraction Technology), has become widely adopted in hospitals and clinics worldwide for its ability to provide accurate readings in challenging clinical conditions such as patient motion or low perfusion.

Since its founding in 1989 by CEO and Chairman Joe Kiani, Masimo has expanded its product portfolio to include rainbow® Pulse CO-Oximetry, which noninvasively measures multiple blood constituents, and SedLine® brain function monitoring for guiding anesthesia and sedation. The company also offers cerebral oximetry devices for monitoring regional oxygen saturation in the brain, acoustic monitoring solutions for respiration rate, and connectivity platforms that integrate data across hospital networks. Masimo’s technologies are designed to improve patient outcomes, reduce the risk of complications, and enhance clinical workflow efficiency.

Masimo’s products are sold in more than 100 countries through a direct sales force and a network of distributors. In addition to its Irvine headquarters, the company maintains regional offices and manufacturing facilities in Europe, Asia, and Latin America. Masimo has pursued strategic acquisitions to complement its core monitoring capabilities, expand its presence in new markets, and accelerate innovation in areas such as consumer health and wearable sensors.

Under the leadership of Joe Kiani and a management team with extensive experience in medical devices and healthcare technology, Masimo continues to invest in research and development to advance noninvasive monitoring. The company’s commitment to patient safety and its track record of delivering clinical evidence have helped establish Masimo as a recognized leader in the global patient monitoring market.

Key Stats

• Today's Range: $163.29 to $171.12
• 50-Day Range: $149.39 to $171.97
• 52-Week Range: $101.61 to $194.88
• Volume: 539,421 shs
• Average Volume: 641,303 shs
• Market Capitalization: $9.16 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $191.60
• Consensus Rating: Moderate Buy

Masimo Stock Analysis - MarketRank™

Masimo scored higher than 88% of companies evaluated by MarketBeat, and ranked 131st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Masimo has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Masimo has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.93%

Earnings Growth

Earnings for Masimo are expected to grow by 12.93% in the coming year, from $4.10 to $4.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Masimo is -18.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Masimo is -18.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Masimo has a P/B Ratio of 8.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.57% of the float of Masimo has been sold short.

Short Interest Ratio / Days to Cover

Masimo has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Masimo has recently increased by 4.79%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Masimo does not currently pay a dividend.

Dividend Growth

Masimo does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.86

Percentage of Shares Shorted

6.57% of the float of Masimo has been sold short.

Short Interest Ratio / Days to Cover

Masimo has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Masimo has recently increased by 4.79%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.82

News Sentiment

Masimo has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Masimo this week, compared to 10 articles on an average week.

Search Interest

5 people have searched for MASI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Masimo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,632,800.00 in company stock.

Percentage Held by Insiders

16.90% of the stock of Masimo is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

85.96% of the stock of Masimo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MASI Stock Analysis - Frequently Asked Questions

How have MASI shares performed this year?

Masimo's stock was trading at $165.30 on January 1st, 2025. Since then, MASI shares have increased by 2.3% and is now trading at $169.0450.
View the best growth stocks for 2025 here.

How were Masimo's earnings last quarter?

Masimo Corporation (NASDAQ:MASI) posted its earnings results on Tuesday, May, 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. The firm's revenue for the quarter was down 24.5% compared to the same quarter last year.
Read the conference call transcript.

Who are Masimo's major shareholders?

Masimo's top institutional shareholders include Kera Capital Partners Inc.. Insiders that own company stock include Joe E Kiani, Bilal Muhsin and Craig B Reynolds.
View institutional ownership trends.

How do I buy shares of Masimo?

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Masimo investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:MASI
• CIK: 937556
• Web: www.masimo.com
• Phone: (949) 297-7000
• Fax: 949-297-7001
• Employees: 6,200
• Year Founded: 1989

Price Target and Rating

• Average Stock Price Target: $191.60
• High Stock Price Target: $200.00
• Low Stock Price Target: $185.00
• Potential Upside/Downside: +13.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 41.22
• P/E Growth: N/A
• Net Income: -$304.90 million
• Net Margins: -25.06%
• Pretax Margin: -14.11%
• Return on Equity: 22.56%
• Return on Assets: 10.00%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 2.17
• Quick Ratio: 1.62

Sales & Book Value

• Annual Sales: $2.09 billion
• Price / Sales: 4.38
• Cash Flow: $6.42 per share
• Price / Cash Flow: 26.33
• Book Value: $19.50 per share
• Price / Book: 8.67

Miscellaneous

• Outstanding Shares: 54,220,000
• Free Float: 45,056,000
• Market Cap: $9.16 billion
• Optionable: Optionable
• Beta: 1.19